CFTR and cystic fibrosis: In comparison to Lumacaftor/Ivacaftor (LUM/IVA) therapy, ELX/TEZ/IVA appears to exhibit more consistent and promising effects on the blood glucose levels, especially in patients with the most common CF mutation in the CFTR gene, F508del (Table 3) [82,83,84,85].